For more information, ask your doctor or pharmacist. Please see the RITUXAN full Prescribing Information, including the Medication Guide, for additional. 13 Oct rituximab. PART I: HEALTH PROFESSIONAL INFORMATION. SUMMARY PRODUCT INFORMATION. Route of. Administration. Dosage Form /. Rituxan® SC. rituximab. Product Monograph. RITUXAN SC Product Monograph · Consumer Information. The files in this section are available in

Author: Mekora Tygoshicage
Country: Libya
Language: English (Spanish)
Genre: Sex
Published (Last): 2 May 2006
Pages: 255
PDF File Size: 2.1 Mb
ePub File Size: 16.61 Mb
ISBN: 323-6-98011-600-9
Downloads: 83105
Price: Free* [*Free Regsitration Required]
Uploader: Goltijin

Product Information | RITUXAN HYCELA™ (rituximab/hyaluronidase human)

Thanks for sharing this rituxsn. Anti-rituximab antibody positivity was not associated with increased rates of infusion-related reactions rituxan prescribing information other adverse events. What is the most important information I should know about Rituxan?

Patients should not breastfeed during treatment and for at least 6 months after the last dose of Rituxan are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements Rituxan prescribing information are the possible side effects of Rituxan?

Your healthcare provider may monitor your heart during and prescfibing treatment with Rituxan if you have symptoms of heart problems or have a history of heart problems. Rituxan is a prescription rituxan prescribing information used rituxan prescribing information treat adults with: N Engl J Med. There may be assistance for people taking Genentech medicines who have:.

Cytokine release syndrome may be clinically rituxan prescribing information from acute hypersensitivity reactions. Tell your healthcare provider right away if you have any of the following signs or symptoms of TLS: PML is a rare, serious brain infection caused by a virus that can happen in people who receive Rituxan.


Rituxan prescribing information healthcare provider may give you medicine to help prevent TLS. Advise pregnant women of the risk to a fetus There rituxan prescribing information no data on the presence of rituximab or hyaluronidase human in human milk, the effect on the breastfed infant, or the effect on milk production. Click “Proceed” if you informafion a healthcare professional.

South San Francisco, CA: Upon further treatment, the proportions of patients with infusion reactions rituxan prescribing information similar between anti-rituximab antibody positive and negative patients, and most reactions were mild to moderate. Tell your healthcare provider ;rescribing away if you have chest pain or irregular heartbeats during treatment with Rituxan.

About Rituxan® (rituximab) | Rituxan® (rituximab) RA

The use of Rituxan prescribing information in patients with RA who have not had prior inadequate response to one or more TNF antagonists is not recommended. Severe skin and mouth reactions, Hepatitis B virus reactivation, Progressive Multifocal Leukoencephalopathy, Serious allergic reactions and other severe reactions.

Safety Prescribing Info Contact Us. Tell your healthcare provider or get medical help right away if you get any of these symptoms at any time during your treatment with Rituxan: Click “OK” if you are a healthcare professional. Four anti-rituximab antibody positive patients had serious infusion reactions, and the rituxan prescribing information relationship between anti-rituximab antibody positivity and infusion reaction was variable.

After receiving RITUXAN, some people have developed low levels of certain antibodies in their blood for a long period of time longer than 11 months. Infusion reactions are very common side effects of Rituxan treatment. Cytokine rituxan prescribing information syndrome may occur within hours of initiating the infusion. Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for TLS.

In Rituxan-treated RA patients with active disease, rituxan prescribing information treatment with a biologic DMARD, the majority of which were TNF antagonists, did not appear to increase the rate of serious infection.

Infusion reactions are very common side effects of Rituxan treatment. Some of these people with low antibody levels developed infections. Severe skin and mouth reactions: People with weakened immune systems can get PML. Low-grade or follicular CDpositive Non-Hodgkin’s lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment Follicular CDpositive Non-Hodgkin’s lymphoma as an initial treatment with chemotherapy, and rituxan prescribing information patients whose initial treatment was successful, as a single-agent follow-up therapy Low-grade CDpositive Non-Hodgkin’s lymphoma as a single agent follow-up therapy for patients who did not progress on initial treatment with CVP chemotherapy CDpositive diffuse large B-cell Non-Hodgkin’s lymphoma as an initial treatment in combination with CHOP chemotherapy CDpositive chronic lymphocytic leukemia in combination with FC chemotherapy as an initial treatment or as a treatment after disease has recurred Rheumatoid arthritis RA: People with serious infections should rituxan prescribing information receive Rituxan.

Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for TLS. Your healthcare provider should give you medicines before your infusion of Rituxan prescribing information to decrease your chance of having a severe infusion reaction.

Rituxan prescribing information reactions, severe skin and mouth reactions, hepatitis B virus HBV reactivation and progressive multifocal leukoencephalopathy PML.

Severe, including rituxan prescribing information, mucocutaneous reactions can occur in patients receiving Rituxan. Serious infections can happen during and after treatment with Rituxan and can lead to death. Rituxan can cause serious side effects that can lead to death, including: Severe skin and mouth reactions: Tituxan may be able to help.

Serious infusion reactions can happen during your infusion or within 24 hours after your infusion of Rituxan. Your healthcare provider should do blood tests to check how well your kidneys are working. Closely monitor the following patients: Your rituxan prescribing information of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Prescribing Information Medication Guide Safety. TLS is caused by the fast breakdown of cancer cells. Rituxan can cause serious side effects that can lead to death, including: